8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Immune System

Park H-J, Choi J-H, Nam M-H, Seo Y-K

Bioeffects Seen

Authors not listed · 2022

Share:

Autoimmune patients with lung complications may be especially vulnerable to EMF-induced immune system disruption.

Plain English Summary

Summary written for general audiences

This 2022 review study examined lung and chest complications in patients with systemic lupus erythematosus (SLE), an autoimmune disease. The researchers found that 20-90% of SLE patients develop lung problems, with one type (diffuse alveolar hemorrhage) having a mortality rate of 68-75%. The study outlined eight different types of lung complications and current diagnostic and treatment approaches.

Why This Matters

While this study focuses on autoimmune disease complications rather than EMF exposure, it highlights an important consideration for the EMF health debate. Autoimmune conditions like lupus involve immune system dysfunction and chronic inflammation - the same biological pathways that multiple studies suggest can be disrupted by electromagnetic field exposure. The reality is that people with existing autoimmune conditions may represent a particularly vulnerable population when it comes to additional environmental stressors, including EMF. The science demonstrates that EMF exposure can trigger inflammatory responses and alter immune function, potentially exacerbating conditions in those already dealing with immune system dysfunction. What this means for you is that if you or a loved one has an autoimmune condition, reducing unnecessary EMF exposure becomes even more important as part of a comprehensive approach to managing environmental triggers.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2022). Park H-J, Choi J-H, Nam M-H, Seo Y-K.
Show BibTeX
@article{park_h_j_choi_j_h_nam_m_h_seo_y_k_ce4173,
  author = {Unknown},
  title = {Park H-J, Choi J-H, Nam M-H, Seo Y-K},
  year = {2022},
  doi = {10.3390/jcm11226714},
  
}
DOI: 10.3390/jcm11226714PubMed: 36431192

Quick Questions About This Study

Yes, lung and chest involvement occurs in 20-90% of SLE patients according to this review. The wide range reflects different types of lung complications, from mild pleural inflammation to life-threatening bleeding.
Diffuse alveolar hemorrhage (DAH) has the highest mortality rate at 68-75%. This condition involves bleeding into the lung's air sacs and requires immediate aggressive treatment with immunosuppressive drugs.
The study identified eight distinct types: lupus pleuritis, pleural effusion, acute pneumonitis, shrinking lung syndrome, interstitial lung disease, diffuse alveolar hemorrhage, pulmonary hypertension, and pulmonary embolism.
The exact mechanism isn't fully understood, but systemic type 1 interferons, circulating immune complexes, and neutrophils appear to play essential roles in triggering lung inflammation and damage.
Rituximab has been successfully used for three specific types: lupus pleuritis, acute lupus pneumonitis, and shrinking lung syndrome, though corticosteroids and cyclophosphamide remain standard treatments.